Why the study?
It was unknown whether beta-blockers reduce mortality or morbidity in patients with heart failure and advanced chronic kidney disease, who are underrepresented in clinical trials.
Does β-blocker use reduce mortality and morbidity in patients with heart failure and advanced chronic kidney disease?
Does β-blocker use reduce mortality and morbidity in patients with heart failure and advanced chronic kidney disease?
Beta-blocker use is associated with reduced mortality and morbidity in patients with HFrEF and advanced CKD, extending known benefits to a population often excluded from randomized trials.
No takes yet. Share an insight, caveat, or question.
May support β-blocker use in HFrEF with advanced CKD; extends observational data but leaves confirmation to RCTs.
Fu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: